Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

697
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
697
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

940
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
940
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

1.0K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.0K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

580
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut-Brain Interaction.

Gastroenterology·2026
Same author

A Message From the Editors.

Alimentary pharmacology & therapeutics·2025
Same author

PPIs and Dementia: The Final Nail in the Coffin?

Digestive diseases and sciences·2025
Same author

Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.

Alimentary pharmacology & therapeutics·2025
Same author

Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication.

Journal of clinical pharmacology·2025
Same journal

Methodological and Reporting Caveats in Evaluating Facility Detection Metrics for Barrett's Esophagus.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Coffee Consumption and Improved Liver Outcomes: Clinical, Imaging, and Proteomic Evidence From the UK Biobank.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Endotype Clustering Contextualizes the Link Between Hepatic Steatosis and High-Risk Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Authors' Reply to the Letter by Dr. Toshikuni on Endotype Clustering, Hepatic Steatosis, and Vulnerable Coronary Plaque.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Blue Notes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

White Paper AGA: Functional Dyspepsia.

Nimish B Vakil1, Colin W Howden2, Paul Moayyedi3

  • 1University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|May 23, 2017
PubMed
Summary
This summary is machine-generated.

Functional dyspepsia (FD) lacks approved treatments. A meeting convened experts, regulators, and patients to discuss progress on a validated patient-reported outcome instrument for FD, outlining future research needs.

Keywords:
DyspepsiaFunctional DyspepsiaPatient-Reported Outcome

More Related Videos

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.1K

Related Experiment Videos

Last Updated: Mar 2, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.1K

Area of Science:

  • Gastroenterology
  • Clinical Therapeutics
  • Patient-Reported Outcomes

Background:

  • Functional dyspepsia (FD) presents a significant clinical challenge globally.
  • There are currently no FDA-approved pharmacotherapies for FD in Western countries.
  • This highlights the urgent need for effective treatment strategies and diagnostic tools.

Framework:

  • A pivotal 2016 meeting in Washington, DC, brought together key stakeholders.
  • Participants included the American Gastroenterological Association (AGA), FDA representatives, pharmaceutical industry experts, and patient advocacy groups.
  • The meeting aimed to foster collaboration and define a path forward for FD research and treatment.

Implementation:

  • Focus on the development and validation of a patient-reported outcome (PRO) instrument.
  • This instrument is crucial for accurately measuring symptom severity and treatment efficacy in FD clinical trials.
  • Progress in PRO instrument development was a key discussion point.

Implications:

  • The white paper summarizes the current landscape of FD research and therapeutic development.
  • It outlines essential future directions and unmet needs in managing FD.
  • Establishing a validated PRO instrument is critical for advancing clinical trials and drug approval processes for FD.